FDA Warning Letter — Damien Sanderlin, MD

Case 328099 — FEI 3009417634

The FDA took a Warning Letter action against Damien Sanderlin, MD on July 27, 2012 (Houston, TX). The action was issued by CBER and concerns biologics products. This facility has 2 recent FDA inspections on record.

Action Details

Facility
Damien Sanderlin, MD
Date
July 27, 2012
Fiscal Year
2012
Product Type
Biologics
Center
CBER
Location
Houston, TX (United States)